O Brien Greene & Co. Inc Purchases 97 Shares of Amgen Inc. (NASDAQ:AMGN)

O Brien Greene & Co. Inc increased its position in Amgen Inc. (NASDAQ:AMGNGet Rating) by 0.4% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 25,047 shares of the medical research company’s stock after buying an additional 97 shares during the quarter. Amgen comprises 2.0% of O Brien Greene & Co. Inc’s holdings, making the stock its 18th largest position. O Brien Greene & Co. Inc’s holdings in Amgen were worth $6,057,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. AIA Group Ltd lifted its position in Amgen by 40.4% in the 1st quarter. AIA Group Ltd now owns 2,938 shares of the medical research company’s stock worth $710,000 after buying an additional 845 shares during the last quarter. Dixon Hughes Goodman Wealth Advisors LLC lifted its position in Amgen by 905.2% in the 1st quarter. Dixon Hughes Goodman Wealth Advisors LLC now owns 1,156 shares of the medical research company’s stock worth $280,000 after buying an additional 1,041 shares during the last quarter. IndexIQ Advisors LLC lifted its position in Amgen by 2.3% in the 1st quarter. IndexIQ Advisors LLC now owns 10,095 shares of the medical research company’s stock worth $2,441,000 after buying an additional 225 shares during the last quarter. Lindbrook Capital LLC increased its stake in Amgen by 16.7% in the 1st quarter. Lindbrook Capital LLC now owns 2,358 shares of the medical research company’s stock worth $570,000 after purchasing an additional 337 shares during the period. Finally, Sante Capital Fund LP purchased a new position in Amgen in the 1st quarter worth approximately $3,118,000. Institutional investors own 77.14% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on AMGN. StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 8th. Oppenheimer reaffirmed an “outperform” rating and issued a $290.00 price target on shares of Amgen in a research note on Thursday, September 1st. Atlantic Securities decreased their price target on Amgen from $190.00 to $182.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 9th. Robert W. Baird reaffirmed an “underperform” rating and issued a $185.00 price target on shares of Amgen in a research note on Tuesday. Finally, Piper Sandler lifted their price target on Amgen from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday, August 5th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $241.13.

Amgen Trading Down 4.5 %

Amgen stock opened at $226.86 on Wednesday. The company has a current ratio of 1.53, a quick ratio of 1.17 and a debt-to-equity ratio of 14.76. The business’s fifty day simple moving average is $246.02 and its two-hundred day simple moving average is $243.53. Amgen Inc. has a 12 month low of $198.64 and a 12 month high of $258.45. The company has a market capitalization of $121.35 billion, a price-to-earnings ratio of 19.23, a price-to-earnings-growth ratio of 2.00 and a beta of 0.56.

Amgen (NASDAQ:AMGNGet Rating) last released its earnings results on Thursday, August 4th. The medical research company reported $4.65 EPS for the quarter, topping the consensus estimate of $4.40 by $0.25. Amgen had a return on equity of 218.34% and a net margin of 24.92%. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.53 billion. During the same period in the previous year, the company posted $4.38 earnings per share. The company’s revenue for the quarter was up 1.0% compared to the same quarter last year. As a group, equities analysts predict that Amgen Inc. will post 17.45 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Thursday, August 18th were issued a $1.94 dividend. This represents a $7.76 annualized dividend and a yield of 3.42%. The ex-dividend date of this dividend was Wednesday, August 17th. Amgen’s dividend payout ratio (DPR) is 65.76%.

Insider Activity

In other news, Director Robert Eckert sold 6,600 shares of the company’s stock in a transaction on Thursday, August 18th. The stock was sold at an average price of $249.00, for a total transaction of $1,643,400.00. Following the transaction, the director now directly owns 21,184 shares of the company’s stock, valued at $5,274,816. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director R Sanders Williams sold 200 shares of the company’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $249.96, for a total transaction of $49,992.00. Following the transaction, the director now directly owns 5,301 shares of the company’s stock, valued at $1,325,037.96. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Robert Eckert sold 6,600 shares of the company’s stock in a transaction on Thursday, August 18th. The shares were sold at an average price of $249.00, for a total value of $1,643,400.00. Following the transaction, the director now directly owns 21,184 shares in the company, valued at $5,274,816. The disclosure for this sale can be found here. Corporate insiders own 0.46% of the company’s stock.

Amgen Company Profile

(Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNGet Rating).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.